Recent Developments in Recombinant Protein-Based Dengue Vaccines

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Sep 8

PMID 30190720

Citations 35

Authors

Nagesh K Tripathi

Ambuj Shrivastava

Affiliations

Soon will be listed here.

Abstract

Recombinant proteins are gaining enormous importance these days due to their wide application as biopharmaceutical products and proven safety record. Various recombinant proteins of therapeutic and prophylactic importance have been successfully produced in microbial and higher expression host systems. Since there is no specific antiviral therapy available against dengue, the prevention by vaccination is the mainstay in reducing the disease burden. Therefore, efficacious vaccines are needed to control the spread of dengue worldwide. Dengue is an emerging viral disease caused by any of dengue virus 1-4 serotypes that affects the human population around the globe. Dengue virus is a single stranded RNA virus encoding three structural proteins (capsid protein, pre-membrane protein, and envelope protein) and seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5). As the only licensed dengue vaccine (Dengvaxia) is unable to confer balanced protection against all the serotypes, therefore various approaches for development of dengue vaccines including tetravalent live attenuated, inactivated, plasmid DNA, virus-vectored, virus-like particles, and recombinant subunit vaccines are being explored. These candidates are at different stages of vaccine development and have their own merits and demerits. The promising subunit vaccines are mainly based on envelope or its domain and non-structural proteins of dengue virus. These proteins have been produced in different hosts and are being investigated for development of a successful dengue vaccine. Novel immunogens have been designed employing various strategies like protein engineering and fusion of antigen with various immunostimulatory motif to work as self-adjuvant. Moreover, recombinant proteins can be formulated with novel adjuvants to enhance the immunogenicity and thus conferring better protection to the vaccinees. With the advent of newer and safer host systems, these recombinant proteins can be produced in a cost effective manner at large scale for vaccine studies. In this review, we summarize recent developments in recombinant protein based dengue vaccines that could lead to a good number of efficacious vaccine candidates for future human use and ultimately alternative dengue vaccine candidates.

Citing Articles

Current status of the development of dengue vaccines.

Lee M, Long C, Poh C Vaccine X. 2025; 22():100604.

PMID: 39830640 PMC: 11741033. DOI: 10.1016/j.jvacx.2024.100604.

Investigation of small molecules disrupting dengue virus assembly by inhibiting capsid protein and blocking RNA encapsulation.

Panday H, Jha A, Dwivedi V Mol Divers. 2024; .

PMID: 39304568 DOI: 10.1007/s11030-024-10980-z.

Approaches of dengue control: vaccine strategies and future aspects.

Akter R, Tasneem F, Das S, Soma M, Georgakopoulos-Soares I, Juthi R Front Immunol. 2024; 15:1362780.

PMID: 38487527 PMC: 10937410. DOI: 10.3389/fimmu.2024.1362780.

Dengue Fever Epidemics and the Prospect of Vaccines: A Systematic Review and Meta-Analysis Using Clinical Trials in Children.

Okoye E, Mitra A, Lomax T, Nunaley C Diseases. 2024; 12(2).

PMID: 38391779 PMC: 10887605. DOI: 10.3390/diseases12020032.

Diagnosis of Imported Dengue and Zika Virus Infections in Italy from November 2015 to November 2022: Laboratory Surveillance Data from a National Reference Laboratory.

Merakou C, Amendola A, Fortuna C, Marsili G, Fiorentini C, Argentini C Viruses. 2024; 16(1).

PMID: 38257751 PMC: 10818496. DOI: 10.3390/v16010050.

References

Avirutnan P, Zhang L, Punyadee N, Manuyakorn A, Puttikhunt C, Kasinrerk W . Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog. 2007; 3(11):e183. PMC: 2092380. DOI: 10.1371/journal.ppat.0030183. View

Wilder-Smith A, Yoon I . Edging closer towards the goal of a dengue vaccine. Expert Rev Vaccines. 2016; 15(4):433-5. DOI: 10.1586/14760584.2016.1154459. View

Clements D, Coller B, Lieberman M, Ogata S, Wang G, Harada K . Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine. 2010; 28(15):2705-15. PMC: 2837772. DOI: 10.1016/j.vaccine.2010.01.022. View

Hu H, Chen H, Hsiao Y, Wu S, Chung H, Hsieh C . The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. Hum Vaccin Immunother. 2016; 12(7):1678-89. PMC: 4964840. DOI: 10.1080/21645515.2016.1143576. View

Alves R, Pereira L, Fabris D, Salvador F, Santos R, Zanotto P . Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen. Clin Vaccine Immunol. 2016; 23(6):460-469. PMC: 4895003. DOI: 10.1128/CVI.00081-16. View

Bauer K, Esquilin I, Santiago Cornier A, Thomas S, Quintero Del Rio A, Bertran-Pasarell J . A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico. Am J Trop Med Hyg. 2015; 93(3):441-453. PMC: 4559678. DOI: 10.4269/ajtmh.14-0625. View

Thisyakorn U, Thisyakorn C . Latest developments and future directions in dengue vaccines. Ther Adv Vaccines. 2014; 2(1):3-9. PMC: 3991153. DOI: 10.1177/2051013613507862. View

Chiang C, Liu S, Hsieh C, Chen M, Tsai J, Liu H . Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice. Vaccine. 2016; 34(8):1054-61. DOI: 10.1016/j.vaccine.2016.01.009. View

Guzman M, Hermida L, Bernardo L, Ramirez R, Guillen G . Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines. 2010; 9(2):137-47. DOI: 10.1586/erv.09.139. View

10.

Ramirez R, Falcon R, Izquierdo A, Garcia A, Alvarez M, Perez A . Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design. Virus Genes. 2014; 49(2):185-95. DOI: 10.1007/s11262-014-1087-3. View

11.

Jacobs M, Robinson P, Bletchly C, Mackenzie J, Young P . Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. FASEB J. 2000; 14(11):1603-10. DOI: 10.1096/fj.14.11.1603. View

12.

Zeidler J, Fernandes-Siqueira L, Barbosa G, Da Poian A . Non-Canonical Roles of Dengue Virus Non-Structural Proteins. Viruses. 2017; 9(3). PMC: 5371797. DOI: 10.3390/v9030042. View

13.

Liu Y, Liu J, Cheng G . Vaccines and immunization strategies for dengue prevention. Emerg Microbes Infect. 2016; 5(7):e77. PMC: 5141265. DOI: 10.1038/emi.2016.74. View

14.

McBurney S, Sunshine J, Gabriel S, Huynh J, Sutton W, Fuller D . Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. Vaccine. 2016; 34(30):3500-7. PMC: 4959041. DOI: 10.1016/j.vaccine.2016.03.108. View

15.

Wong S, Haqshenas G, Gowans E, Mackenzie J . The dengue virus M protein localises to the endoplasmic reticulum and forms oligomers. FEBS Lett. 2012; 586(7):1032-7. DOI: 10.1016/j.febslet.2012.02.047. View

16.

Thomas S, Eckels K, Carletti I, de La Barrera R, Dessy F, Fernandez S . A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg. 2012; 88(1):73-88. PMC: 3541749. DOI: 10.4269/ajtmh.2012.12-0361. View

17.

Tripathi L, Mani S, Raut R, Poddar A, Tyagi P, Arora U . Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies. Front Microbiol. 2015; 6:1005. PMC: 4585145. DOI: 10.3389/fmicb.2015.01005. View

18.

Liu W, Chen H, Wang X, Huang H, Khromykh A . Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J Virol. 2004; 78(22):12225-35. PMC: 525072. DOI: 10.1128/JVI.78.22.12225-12235.2004. View

19.

Urakami A, Ngwe Tun M, Moi M, Sakurai A, Ishikawa M, Kuno S . An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design. J Virol. 2017; 91(23). PMC: 5686733. DOI: 10.1128/JVI.01181-17. View

20.

Tripathi N, Shrivastava A . Evaluation of antibody response against recombinant domain III proteins of dengue virus type 1 and 2. AIMS Microbiol. 2019; 3(2):248-266. PMC: 6605013. DOI: 10.3934/microbiol.2017.2.248. View